Cholesterol on trial? But it's not necessarily bad: Professor Ursini debunks false myths (and what statins and pharmaceutical marketing have to do with it)

Fulvio Ursini, an emeritus professor of Biochemistry at the University of Padova, has challenged the widespread belief that high cholesterol levels are inherently dangerous, arguing that such views are based more on statistical correlations than on solid biochemical evidence. In his book Processo al colesterolo (The Trial of Cholesterol), co-authored with Paola Arosio, Ursini presents a critical examination of the medical community’s approach to cholesterol, likening it to a legal trial complete with investigation, accusations, defense, and potential judgment. He contends that the lowering of cholesterol risk thresholds over time, once set at 260 mg/dL forty years ago, then 250 mg/dL ten years ago, and now 200 mg/dL, is driven more by cultural shifts than scientific necessity. Ursini questions the basis of current medical practices regarding cholesterol, emphasizing the difference between correlation and causation. He argues that while there is clear evidence linking smoking to lung cancer, the same level of certainty does not apply to the relationship between cholesterol and heart disease. He uses an analogy to illustrate this point: just because firefighters are present at fires does not mean they cause them. Similarly, he suggests that the presence of cholesterol in arteries does not necessarily mean it causes blockages or damage. He further differentiates between relative and absolute risk, pointing out how pharmaceutical marketing often emphasizes relative risk reduction. For example, a drug might claim to reduce the risk of a heart attack by 50 percent, which sounds dramatic. However, if the initial risk was two in 100 people, reducing it to one in 100 means the benefit applies to only one person in 100 who takes the medication. This distinction, according to Ursini, is crucial for understanding the true impact of such treatments. Despite these arguments, many doctors still advise patients to worry about high cholesterol levels. Ursini attributes this to a form of paternalism practiced by both physicians and medical guidelines. He notes that cholesterol is not an alien substance within the body, it plays essential roles in producing vitamin D, forming cell membranes, and synthesizing hormones. The molecule itself is not inherently harmful, and its importance is underscored by the fact that thirteen Nobel Prizes have been awarded for research related to cholesterol physiology, none of which reference its supposed "evil" nature. The real issue, according to Ursini, lies in low-density lipoprotein (LDL) particles. These particles function similarly to trucks, transporting cholesterol throughout the body. They become problematic not when their numbers increase, but when they malfunction, deviating from their intended path and becoming lodged in arterial walls. At this point, the body recognizes them as foreign and potentially harmful, triggering inflammatory and oxidative responses that could lead to heart attacks or strokes. Regarding the widespread use of statins, Ursini acknowledges their value in specific cases, particularly for individuals with familial hypercholesterolemia, a genetic condition affecting approximately one in 300,000 people. Statins are effective in managing this rare disorder, where the body struggles to absorb LDL into cells. However, he cautions against their routine prescription for the majority of the population, noting that 85 percent of people do not suffer from this genetic condition. His critique extends beyond individual health concerns, suggesting that the global reliance on statins may reflect broader issues of pharmaceutical marketing and the influence of industry interests on medical practice. Ursini's work has sparked debate among medical professionals and researchers, some of whom support his call for a more nuanced understanding of cholesterol’s role in human biology. Others argue that the statistical data linking high cholesterol to cardiovascular disease remains robust and that preventive measures, including lifestyle changes and medication, continue to save lives. As discussions around cholesterol management evolve, the need for rigorous scientific inquiry and transparency in medical decision-making becomes increasingly apparent.